{"id":"NCT01175590","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle","officialTitle":"A Study to Evaluate the Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Following Three Times Daily(TID) Dosing for 7 Days","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2011-12","completion":"2012-02","firstPosted":"2010-08-05","resultsPosted":"2013-05-01","lastUpdate":"2013-05-01"},"enrollment":518,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Besivance","otherNames":[]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"Besivance","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.","primaryOutcome":{"measure":"Ocular Treatment Emergent Adverse Events","timeFrame":"At each visit - 7 days","effectByArm":[{"arm":"Besivance","deltaMin":3,"sd":null},{"arm":"Vehicle","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":347},"commonTop":[]}}